Clinical Trial Update: Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma [Phase 2]

View source ↗

Summary

Phase 2 trial update of dinutuximab with sargramostim in recurrent osteosarcoma has completed enrollment with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteosarcoma

Drugs mentioned

• dinutuximab (dinutuximab)
• sargramostim (sargramostim)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma | Phase 2 | Status: COMPLETED | Results posted: 2021-05-07